Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided herein are the metalloborane compounds, MOF-metalloborane compositions, and hydrogen storage system used for high density hydrogen storage. The compounds and compositions may have the structure M2B6H6 or MOF-M2B6H6-dicarboxylic acid. Particularly the transition metal M may be titanium or scandium and the MOF may be MOF5. The hydrogen storage systems hydrogen absorbed to the metalloborane compounds or to the MOF-metalloborane compositions. Methods of storing hydrogen are provided comprising flowing or passing hydrogen gas for absorptive contact with the metalloborane compounds or to the MOF-metalloborane compositions. Also provided is a method for calculating the hydrogen storage capacity of a metalloborane is provided in which random sampling of the thermodynamic states of a two-system model of hydrogen in the presence of a metal organic framework-metalloborane crystal structure is used to calculate probability of hydrogen absorption.

Abstract: Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.

Abstract: Provided herein are formulations and co-solvent formulations and methods for treating an infectious disease utilizing the same. The formulations and co-solvent formulations may comprise a hydroxyquinoline analog or its pharmaceutically acceptable salt, a solvent and at least two surfactants. Also provided are methods of quantitating a hydroxyquinoline analog in a sample via chromatographic/spectrometric measurements.

Abstract: Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.

Abstract: Provided herein are the metalloborane compounds, MOF-metalloborane compositions, and hydrogen storage system used for high density hydrogen storage. The compounds and compositions may have the structure M2B6H6 or MOF-M2B6H6-dicarboxylic acid. Particularly the transition metal M may be titanium or scandium and the MOF may be MOF5. The hydrogen storage systems hydrogen absorbed to the metalloborane compounds or to the MOF-metalloborane compositions. Methods of storing hydrogen are provided comprising flowing or passing hydrogen gas for absorptive contact with the metalloborane compounds or to the MOF-metalloborane compositions. Also provided is a method for calculating the hydrogen storage capacity of a metalloborane is provided in which random sampling of the thermodynamic states of a two-system model of hydrogen in the presence of a metal organic framework-metalloborane crystal structure is used to calculate probability of hydrogen absorption.

Abstract: The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof.

Abstract: The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof.

Abstract: The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof.

Abstract: Provided herein is a pharmaceutical injectable formulation of itraconazole (10 mg/g) where the formulation comprises a solubilizer, a nonionic surfactant/emulsifier, a co-surfactant and a stabilizer. Further provided is a pharmaceutical formulation of itraconazole, said formulation comprising a solubilizer in a concentration of from about 20% to about 75%, a nonionic surfactant/emulsifier in a concentration of from about 20% to about 50%, a co-surfactant in a concentration from about 10% to about 45% and a stabilizer in a concentration of from about 1% to about 15%.

Abstract: Provided herein are systems for locating one or more hazardous material incidents, for example, a petrochemical incident, in a geographical area of interest. The system generally comprises electronic device with at least a processor, a memory and a display coupled to the processor and at least one network connection; and a user interactive tool coupled to the electronic device. Particularly, the interactive tool or interactive mapping tool comprises activatable widgets in an interface, databases accessible by the widgets and a mapping application and displayable interactive base map. Also provided is a method and utilizing the system to locate hazardous material incidents by activating the widgets, querying the databases and displaying incident data retrieved from the databases on the base map. Further provided is a non-transitory machine-readable storage device comprising processor-executable instructions to perform the method.

Abstract: A method comprising: dispersing carbon nanotubes in a solvent; and depositing the carbon nanotubes on a porous, conductive substrate; wherein the porous, conductive substrate is capable of functioning as a filter and a working electrode. The method of claim 1 further comprising: engaging the porous, conductive substrate with deposited carbon nanotubes in an electrochemical cell; and depositing at least one metallic structure on the surface of the carbon nanotubes from an electrolyte solution to form metallized carbon nanotubes. A composite comprising: metallized carbon nanotubes generated by the method of claim 2; wherein the at least one metallic structure comprises a conductive metal atom selected from the group consisting of platinum, gold nickel, copper, iron, chromium, zinc, and combinations thereof; and a matrix material selected from the group consisting of epoxies, thermosets, thermoplastics, elastomers, metals, metal matrix composites, ceramics and combinations thereof.

Abstract: Provided herein is a pharmaceutical formulation of etravirine, said formulation comprising: etravirine; a dipolar aprotic solvent; a non-ionic water dispersible surfactant; and water. Further provided is a pharmaceutical formulation of etravirine, said formulation comprising: etravirine; a non-ionic water dispersible surfactant; and water.

Abstract: A method comprising: dispersing carbon nanotubes in a solvent; and depositing the carbon nanotubes on a porous, conductive substrate; wherein the porous, conductive substrate is capable of functioning as a filter and a working electrode. The method of claim 1 further comprising: engaging the porous, conductive substrate with deposited carbon nanotubes in an electrochemical cell; and depositing at least one metallic structure on the surface of the carbon nanotubes from an electrolyte solution to form metallized carbon nanotubes. A composite comprising: metallized carbon nanotubes generated by the method of claim 2; wherein the at least one metallic structure comprises a conductive metal atom selected from the group consisting of platinum, gold nickel, copper, iron, chromium, zinc, and combinations thereof; and a matrix material selected from the group consisting of epoxies, thermosets, thermoplastics, elastomers, metals, metal matrix composites, ceramics and combinations thereof.